



PCT/GB04/2504



INVESTOR IN PEOPLE

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 06 JUL 2004

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*Andrew Gersey*

Dated 24 June 2004


**BEST AVAILABLE COPY**



1/77

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

1. Your reference

CR 2A

2. Patent application number

(The Patent Office will fill this part in)

0329998.9

28DEC03 E862125-1 C70969  
P01/7700 0.00 0329998.9 NONE

3. Full name, address and postcode of the or of each applicant (underline all surnames)

23 DEC 2003  
CHROMA THERAPEUTICS LIMITED  
92 MILTON PARK  
ABINGDON  
OXFORDSHIRE OX4 4RY

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

ENGLAND

8280414007

4. Title of the invention

ENZYME INHIBITORS

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

ALAN J. WALLS  
P.O. BOX 223  
TADWORTH  
SURREY KT20 5YF

Patents ADP number (if you know it)

8100 77800

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

N/A

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application

Date of filing  
(day / month / year)

N/A

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

YES

NOT AVAILABLE COPY

# Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form	0
Description	27
Claim(s)	6
Abstract	0
Drawing(s)	0

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	0
Request for a preliminary examination and search (Patents Form 9/77)	0
Request for a substantive examination (Patents Form 10/77)	0
Any other documents (please specify)	0

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

*Alan Walls*

Date 22/12/2003

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

ALAN J. WALLS 01737 813849

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

## **Enzyme Inhibitors**

This invention relates to compounds which inhibit members of the histone deacetylase family of enzymes and to their use in the treatment of cell proliferative diseases, including cancers, polyglutamine diseases for example Huntingdon disease, neurogenerative diseases for example Alzheimer disease, autoimmune disease and organ transplant rejection, diabetes, haematological disorders and infection.

## **Background to the Invention**

In eukaryotic cells DNA is packaged with histones, to form chromatin.

Approximately 150 base pairs of DNA are wrapped twice around an octamer of histones (two each of histones 2A, 2B, 3 and 4) to form a nucleosome, the basic unit of chromatin. The ordered structure of chromatin needs to be modified in order to allow transcription of the associated genes.

Transcriptional regulation is key to differentiation, proliferation and apoptosis, and is, therefore, tightly controlled. Control of the changes in chromatin structure (and hence of transcription) is mediated by covalent modifications to histones, most notably of the N-terminal tails. Covalent modifications (for example methylation, acetylation, phosphorylation and ubiquitination) of the side chains of amino acids are enzymatically mediated (A review of the covalent modifications of histones and their role in transcriptional regulation can be found in Berger SL 2001 *Oncogene* 20, 3007-3013; See Grunstein, M 1997 *Nature* 389, 349-352; Wolffe AP 1996 *Science* 272, 371-372; and Wade PA et al 1997 *Trends Biochem Sci* 22, 128-132 for reviews of histone acetylation and transcription).

Acetylation of histones is associated with areas of chromatin that are transcriptionally active, whereas nucleosomes with low acetylation levels are, typically, transcriptionally silent. The acetylation status of histones is controlled by two enzyme classes of opposing activities; histone acetyltransferases (HATs) and histone deacetylases (HDACs). In transformed cells it is believed that inappropriate expression of HDACs results in silencing of tumour suppressor genes (For a review of the potential roles of HDACs in tumorigenesis see Gray SG and Teh BT 2001 *Curr Mol Med* 1, 401-429).

Inhibitors of HDAC enzymes have been described in the literature and shown to induce transcriptional reactivation of certain genes resulting in the inhibition of cancer cell proliferation, induction of apoptosis and inhibition of tumour growth in animals (For review see Kelly, WK et al 2002 Expert Opin Investig Drugs 11, 1695-1713). Such findings suggest that HDAC inhibitors have therapeutic potential in the treatment of proliferative diseases such as cancer (Kramer, OH et al 2001 Trends Endocrinol 12, 294-300, Vigushin DM and Coombes RC 2002 Anticancer Drugs 13, 1-13).

In addition, others have proposed that aberrant HDAC activity or histone acetylation is implicated in the following diseases and disorders; polyglutamine disease, for example Huntingdon disease (Hughes RE 2002 Curr Biol 12, R141-R143; McCampbell A et al 2001 Proc Soc Natl Acad Sci 98, 15179-15184; Hockly E et al 2003 Proc Soc Natl Acad Sci 100, 2041-2046), other neurodegenerative diseases, for example Alzheimer disease (Hempen B and Brion JP 1996, J Neuropathol Exp Neurol 55, 964-972), autoimmune disease and organ transplant rejection (Skov S et al 2003 Blood 101, 14 30-1438; Mishra N et al 2003 J Clin Invest 111, 539-552), diabetes (Mosley AL and Ozcan S 2003 J Biol Chem 278, 19660 - 19666) and diabetic complications, infection (including protozoal infection (Darkin-Rattray, SJ et al 1996 Proc Soc Natl Acad Sci 93, 13143-13147)) and haematological disorders including thalassemia (Witt O et al 2003 Blood 101, 2001-2007). The observations contained in these manuscripts suggest that HDAC inhibition should have therapeutic benefit in these, and other related, diseases.



### **Brief Description of the Invention**

This invention is based on the finding that a class of tricyclic nitrogen-containing compounds having a hydroxamate or N-hydroxy acylamino metal binding group are capable of inhibiting the activity of members of the HDAC family, including HDAC1, and are of value in the treatment of diseases mediated by excessive or inappropriate HDAC, especially HDAC1 activity, such as cell-proliferative diseases, including cancers, polyglutamine diseases for example Huntingdon disease, neurodegenerative diseases for example

Alzheimer disease, autoimmune disease and organ transplant rejection, diabetes, haematological disorders and infection (including but not limited to protozoal and fungal).

### **Detailed Description of the Invention**

In a broad aspect, the present invention provides a compound of formula (IA) or (IB), or a salt, hydrate or solvate thereof.



wherein

fused rings A<sup>1</sup> and A<sup>2</sup> are optionally substituted;

R<sub>1</sub> represents a radical of formula  $-(\text{Alk}^1)_n-(\text{X})_m-(\text{Alk}^2)_p-\text{Z}$  wherein

Z represents a radical of formula  $-\text{C}(=\text{O})\text{NH}(\text{OH})$ , or  $-\text{N}(\text{OH})\text{C}(=\text{O})\text{Y}$  wherein Y represents hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, a phenyl or cycloalkyl ring, or a monocyclic heterocyclic radical having 5 or 6 ring atoms;

Alk<sup>1</sup> represents an optionally substituted, straight or branched, C<sub>1</sub>-C<sub>6</sub> alkylene radical,

Alk<sup>2</sup> represents an optionally substituted, straight or branched, C<sub>1</sub>-C<sub>6</sub> alkylene, C<sub>2</sub>-C<sub>6</sub> alkenylene or C<sub>2</sub>-C<sub>6</sub> alkynylene radical which may optionally contain an ether (–O–), thioether (–S–) or amino (–NR<sup>A</sup>–) link wherein R<sup>A</sup> is hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl;

X represents an optionally substituted phenyl or 5- or 6-membered heteroaryl ring; and

$n$ ,  $m$  and  $p$  are independently 0 or 1, provided that at least one of  $n$ ,  $m$  and  $p$  is 1 and the length of radical  $-(\text{Alk}^1)_n-(\text{X})_m-(\text{Alk}^2)_p-$  is equivalent to that of a hydrocarbon chain of from 2-10 carbon atoms;

$\text{R}^1_2$  is hydrogen and  $\text{R}_2$  is (a) an optional substituent or (b) a radical of formula  $-(\text{Alk}^3)_r-\text{Q}$  wherein  $r$  is 0 or 1,  $\text{Alk}^3$  represents an optionally substituted, straight or branched,  $\text{C}_1\text{-C}_6$  alkylene,  $\text{C}_2\text{-C}_6$  alkenylene or  $\text{C}_2\text{-C}_6$  alkynylene radical and  $\text{Q}$  is hydrogen or an optionally substituted carbocyclic or heterocyclic group; or  $\text{R}^1_2$  and  $\text{R}_2$  taken together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring;

$\text{R}^1_3$  is hydrogen and  $\text{R}_3$  is (i) an optional substituent or (ii) a radical of formula  $-(\text{Alk}^3)_r-\text{Q}$  wherein  $r$  is 0 or 1,  $\text{Alk}^3$  represents an optionally substituted, straight or branched,  $\text{C}_1\text{-C}_6$  alkylene,  $\text{C}_2\text{-C}_6$  alkenylene or  $\text{C}_2\text{-C}_6$  alkynylene radical and  $\text{Q}$  is hydrogen or an optionally substituted carbocyclic or heterocyclic group; or  $\text{R}^1_3$  and  $\text{R}_3$  taken together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring; and

$\text{R}_4$  is hydrogen or  $\text{C}_1\text{-C}_6$  alkyl.

In another broad aspect the invention provides the use of a compound of formula (I) as defined above, or a salt, hydrate or solvate thereof in the preparation of a composition for inhibiting the activity of an HDAC enzyme.

The compounds with which the invention is concerned may be used for the inhibition of HDAC activity, particularly HDAC1 activity, *ex vivo* or *in vivo*.

In one aspect of the invention, the compounds of the invention may be used in the preparation of a composition for the treatment of cell-proliferation disease, for example cancer cell proliferation, polyglutamine diseases for example Huntington disease, neurodegenerative diseases for example Alzheimer disease, autoimmune disease and organ transplant rejection, diabetes,

haematological disorders and infection (including but not limited to protozoal and fungal).

In another aspect, the invention provides a method for the treatment of cell-proliferation disease, for example cancer cell proliferation, polyglutamine diseases for example Huntingdon disease, neurogenerative diseases for example Alzheimer disease, autoimmune disease and organ transplant rejection, diabetes, haematological disorders and infection (including but not limited to protozoal and fungal), which comprises administering to a subject suffering such disease an effective amount of a compound of formula (I) as defined above.

As used herein the term "(C<sub>1</sub>-C<sub>6</sub>)alkyl" means a straight or branched chain alkyl moiety having from 1 to 6 carbon atoms, including for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl and n-hexyl.

As used herein the term "(C<sub>1</sub>-C<sub>6</sub>)alkylene radical" means a divalent saturated hydrocarbon chain having from 1 to 6 carbon atoms .

As used herein the term "(C<sub>2</sub>-C<sub>6</sub>)alkenyl" means a straight or branched chain alkenyl moiety having from 2 to 6 carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. The term includes, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl.

As used herein the term "divalent (C<sub>2</sub>-C<sub>6</sub>)alkenylene radical" means a divalent hydrocarbon chain having from 2 to 6 carbon atoms, and at least one double bond.

As used herein the term "C<sub>2</sub>-C<sub>6</sub> alkynyl" refers to straight chain or branched chain hydrocarbon groups having from two to six carbon atoms and having in addition one triple bond. This term would include for example, ethynyl, 1-propynyl, 1- and 2-butylnyl, 2-methyl-2-propynyl, 2-pentylnyl, 3-pentylnyl, 4-pentylnyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl.



As used herein the term "divalent ( $C_2-C_6$ )alkynylene radical" means a divalent hydrocarbon chain having from 2 to 6 carbon atoms, and at least one triple bond.

As used herein the term "cycloalkyl" refers to a saturated carbocyclic radical having from 3-8 carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

As used herein the term "cycloalkenyl" refers to a carbocyclic radical having from 3-8 carbon atoms containing at least one double bond, and includes, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.

As used herein the term "aryl" refers to a mono-, bi- or tri-cyclic carbocyclic aromatic radical. Illustrative of such radicals are phenyl, biphenyl and naphthyl.

As used herein the term "carbocyclic" refers to a cyclic radical whose ring atoms are all carbon, and includes aryl, cycloalkyl and cycloalkenyl radicals.

As used herein the term "heteroaryl" refers to an aromatic radical containing one or more heteroatoms selected from S, N and O. Illustrative of such radicals are thienyl, benzthienyl, furyl, benzfuryl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, benzthiazolyl, isothiazolyl, benzisothiazolyl, pyrazolyl, oxazolyl, benzoxazolyl, isoxazolyl, benzisoxazolyl, isothiazolyl, triazolyl, benztriazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl and indazolyl.

As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in particular means a non-aromatic radical containing one or more heteroatoms selected from S, N and O. Illustrative of such radicals are pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzfuranyl, pyranyl, isoxazolyl,

benzimidazolyl, methylenedioxyphenyl, ethylenedioxyphenyl, maleimido and succinimido groups.

Unless otherwise specified in the context in which it occurs, the term "substituted" as used herein means substituted with at least one substituent, for example selected from (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, mercapto, mercapto(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, trifluoromethylsulfonyl, nitro, nitrile (-CN), oxo, phenyl, -COOH, -COOR<sup>A</sup>, -COR<sup>A</sup>, -SO<sub>2</sub>R<sup>A</sup>, -CONH<sub>2</sub>, -SO<sub>2</sub>NH<sub>2</sub>, -CONHR<sup>A</sup>, -SO<sub>2</sub>NHR<sup>A</sup>, -CONR<sup>A</sup>R<sup>B</sup>, -SO<sub>2</sub>NR<sup>A</sup>R<sup>B</sup>, -NH<sub>2</sub>, -NHR<sup>A</sup>, -NR<sup>A</sup>R<sup>B</sup>, -OCONH<sub>2</sub>, -OCONHR<sup>A</sup>, -OCONR<sup>A</sup>R<sup>B</sup>, -NHCOR<sup>A</sup>, -NHCOOR<sup>A</sup>, -NR<sup>B</sup>COOR<sup>A</sup>, -NHCO<sub>2</sub>OR<sup>A</sup>, -NR<sup>B</sup>SO<sub>2</sub>OR<sup>A</sup>, -NHCONH<sub>2</sub>, -NR<sup>A</sup>CONH<sub>2</sub>, -NHCONHR<sup>B</sup>, -NR<sup>A</sup>CONHR<sup>B</sup>, -NHCONR<sup>A</sup>R<sup>B</sup>, or -NR<sup>A</sup>CONR<sup>A</sup>R<sup>B</sup> wherein R<sup>A</sup> and R<sup>B</sup> are independently a (C<sub>1</sub>-C<sub>6</sub>)alkyl or (C<sub>3</sub>-C<sub>8</sub>) cycloalkyl group. As used herein the term "optional substituent" includes one of the foregoing substituents.

As used herein the term "salt" includes base addition, acid addition and quaternary salts. Compounds of the invention which are acidic can form salts, including pharmaceutically or veterinarily acceptable salts, with bases such as alkali metal hydroxides, e.g. sodium and potassium hydroxides; alkaline earth metal hydroxides e.g. calcium, barium and magnesium hydroxides; with organic bases e.g. N-ethyl piperidine, dibenzylamine and the like. Those compounds (I) which are basic can form salts, including pharmaceutically or veterinarily acceptable salts with inorganic acids, e.g. with hydrohalic acids such as hydrochloric or hydrobromic acids, sulphuric acid, nitric acid or phosphoric acid and the like, and with organic acids e.g. with acetic, tartaric, succinic, fumaric, maleic, malic, salicylic, citric, methanesulphonic and p-toluene sulphonic acids and the like.

Some compounds of the invention contain one or more actual or potential chiral centres because of the presence of asymmetric carbon atoms. The presence of several asymmetric carbon atoms gives rise to a number of

diastereoisomers with R or S stereochemistry at each chiral centre. The invention includes all such diastereoisomers and mixtures thereof.

#### The group $R_1$

The group Z in  $R_1$  is a hydroxamate group  $-C(=O)NHOH$  or N-hydroxyacylamino group  $-N(OH)C(=O)Y$ , which functions as a metal binding group, interacting with the metal ion at the active site of the HDAC enzyme. At present a hydroxamate group or N-hydroxyformylamino group is preferred.

The radical  $-(Alk^1)_n-(X)_m-(Alk^2)_p-$  in  $R_1$  functions as a linker radical, the length of which is equivalent to a chain of from 2 to 10 carbons, for example 4 to 9 carbons, more particularly 5 to 8 carbons, and especially 6 carbons.

In the linker radical  $-(Alk^1)_n-(X)_m-(Alk^2)_p-$ ,  $Alk^1$  and  $Alk^2$  when present independently represent an optionally substituted, straight or branched,  $C_1$ - $C_6$  alkylene,  $C_2$ - $C_6$  alkenylene or  $C_2$ - $C_6$  alkynylene radical. Presently it is preferred that any branching be modest, and indeed unbranched  $Alk^1$  and  $Alk^2$  radicals are currently most preferred. Similarly, although substitution is optional in  $Alk^1$  and  $Alk^2$ , it is presently preferred that they be unsubstituted. Examples of  $Alk^1$  and  $Alk^2$  radicals include  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2-$ ,  $-CH=CH-$ ,  $-CH=CHCH_2-$ ,  $-CH_2CH=CH-$ ,  $CH_2CH=CHCH_2-$ ,  $-C\equiv C-$ ,  $-C\equiv CCH_2-$ ,  $-CH_2C\equiv C-$ , and  $CH_2C\equiv CCH_2$ . Additional examples of  $Alk^2$  include  $-CH_2W-$ ,  $-CH_2CH_2W-$ ,  $-CH_2CH_2WCH_2-$ ,  $-CH_2CH_2WCH(CH_3)-$ ,  $-CH_2WCH_2CH_2-$ ,  $-CH_2WCH_2CH_2WCH_2-$ , and  $-WCH_2CH_2-$  where W is  $-O-$ ,  $-S-$ ,  $-NH-$  or  $-N(CH_3)-$ .

In the linker radical  $-(Alk^1)_n-(X)_m-(Alk^2)_p-$ , X when present represents an optionally substituted phenyl or 5- or 6-membered heteroaryl ring. Presently it is preferred that the ring X be unsubstituted. Examples of rings X include phenyl, pyridine, thiophene, and furan rings, but phenyl is presently preferred.

In the linker radical  $-(Alk^1)_n-(X)_m-(Alk^2)_p-$ , n, m and p are independently 0 or 1, but since the linker radical must be present, at least one of n, m and p is 1. When m is 0, the linker radical is a hydrocarbon chain (optionally substituted and, depending on the identity of  $Alk^2$ , perhaps having an ether, thioether or

amino linkage). When both  $n$  and  $p$  are 0, the linker radical is a divalent phenyl or heteroaryl radical (optionally substituted). When  $m$  is 1 and at least one of  $n$  and  $p$  is 1, the linker radical is a divalent radical including a hydrocarbon chain or chains and a divalent phenyl or heteroaryl radical. In a particular subset of compounds of the invention the linker radical is an unsubstituted, unbranched, saturated hydrocarbon chain of from 4 to 9 carbons, more particularly 5 to 8 carbons, and especially 6 carbons.

The substituents  $R^1_2$  and  $R_2$ , and  $R^1_3$  and  $R_3$

In the fused tetrahydropyridine ring of compounds (IA) and (IB), when  $R^1_2$  is hydrogen  $R_2$  may be any of the optional substituents listed above, such as trifluoromethyl, methyl, ethyl *n*- and iso-propyl, methoxy, ethoxy, methylenedioxy, ethylenedioxy, amino, mono- and di-methylamino, mono- and di-ethylamino, nitro, cyano, fluoro, chloro, bromo, and methylsulfonylamino.

Alternatively, when  $R^1_2$  is hydrogen  $R_2$  may be a radical of formula  $-(Alk^3)_r-Q$  as defined above. In such radicals,  $r$  is 0 or 1;  $Alk^3$  may be, for example,  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2-$ ,  $-CH=CH-$ ,  $-CH=CHCH_2-$ ,  $-CH_2CH=CH-$ ,  $CH_2CH=CHCH_2-C\equiv C-$ ,  $-C\equiv CCH_2-$ ,  $-CH_2C\equiv C-$ ,  $-CH_2C\equiv CCH_2-$  or  $-CH_2W-$ ,  $-CH_2CH_2W-$ ,  $-CH_2CH_2WCH_2-$ ,  $-CH_2WCH_2CH_2-$ ,  $-CH_2WCH_2CH_2WCH_2-$ , and  $-WCH_2CH_2-$  where  $W$  is  $-O-$ ,  $-S-$ ,  $-NH-$  or  $-N(CH_3)-$ ; and  $Q$  may be, for example, hydrogen or an optionally substituted phenyl, pyridyl, pyrimidinyl, thienyl, furanyl, cyclopropyl, cyclopentyl, cyclohexyl, piperidinyl, or morpholinyl. Presently  $Alk^3$  radicals which do not include ether, thioether or amino links, are preferred. Amongst rings  $Q$  which are presently preferred are phenyl, 4-pyridyl, and pyrimidin-2-yl. Optional substituents in rings  $Q$  may be selected from those listed above in the definition of the term "optionally substituted". Examples of such substituents include trifluoromethyl, methoxy, methylenedioxy, ethylenedioxy, nitro, cyano, fluoro, chloro and bromo.

In a further alternative,  $R^1_2$  and  $R_2$  taken together with the carbon atoms to which they are attached may form an optionally substituted carbocyclic or

heterocyclic ring, forming a spiro structure. Examples of such spiro-linked rings include cyclohexyl, piperidinyI spiro-linked at the 4-position, and pyrrolidinyI spiro-linked at the 2-position.

The above discussion of  $R^1_2$ ,  $R_2$  substituents applies also to  $R^1_3$  and  $R_3$ .

#### The Substituent $R_4$

$R_4$  may be, for example, hydrogen, methyl, ethyl or n- or iso-propyl. Presently hydrogen is preferred.

#### The Fused Rings $A^1$ and $A^2$

These rings are optionally substituted. Examples of optional substituents include trifluoromethyl, methyl, ethyl n- and iso-propyl, methoxy, ethoxy, methylenedioxy, ethylenedioxy, amino, mono- and di-methylamino, mono- and di-ethylamino, nitro, cyano, fluoro, chloro, bromo, and methylsulfonylamino.

Specific Examples of compounds for use in accordance with the invention include those of the Examples herein.

Hydroxamate compounds (IA) and (IB) of the invention may be prepared from the corresponding carboxylic acids, ie compounds (IA) and (IB) wherein in group  $R_1$  Z is  $-\text{COOH}$  by causing that acid or an activated derivative thereof to react with hydroxylamine, O-protected hydroxylamine, or an N,O-diprotected hydroxylamine, or a salt thereof, then removing the protecting groups from the resultant hydroxamic acid moiety (and from any protected substituents in the compound).

Conversion of the acid to an activated derivative such as the pentafluorophenyl, hydroxysuccinyl, or hydroxybenzotriazolyl ester may be effected by reaction with the appropriate alcohol in the presence of a dehydrating agent such as dicyclohexyl dicarbodiimide (DCC), N,N-dimethylaminopropyl-N'-ethyl carbodiimide (EDC), or 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ).

Protecting groups for protection of reactive moieties in (II) during the reaction with hydroxylamine are well known per se, for example from the techniques of peptide chemistry. Amino groups are often protectable by benzyloxycarbonyl, t-butoxycarbonyl or acetyl groups, or in the form of a phthalimido group.




Hydroxy groups are often protectable as readily cleavable ethers such as the t-butyl or benzyl ether, or as readily cleavable esters such as the acetate.

Carboxy groups are often protectable as readily cleavable esters, such as the t-butyl or benzyl ester.

Examples of O-protected hydroxylamines for use in the above method include O-benzylhydroxylamine, O-4-methoxybenzylhydroxylamine, O-trimethylsilylhydroxylamine, and O-tert-butoxycarbonylhydroxylamine.

Examples of O,N-diprotected hydroxylamines for use in the above method include N,O-bis(benzyl)hydroxylamine, N,O-bis(4-methoxybenzyl)hydroxylamine, N-tert-butoxycarbonyl-O-tert-butyltrimethylsilylhydroxylamine, N-tert-butoxycarbonyl-O-tetrahydropyranylmethylhydroxylamine, and N,O-bis(tert-butoxycarbonylmethyl)hydroxylamine.

Carboxylic acid analogues of compounds (IA) and (IB) may be prepared by coupling the tricyclic amine (IIA) or (IIB) with the carboxylic acid (III) or an activated derivative thereof





(III)

in which V is a protected carboxylic acid group, and thereafter removing the carboxy protecting group.



Condensation of the acid (III) with the amine (IIA) or (IIB) may be facilitated by dehydrating agents such as those referred to above.

In an alternative synthesis of compounds (IA) and (IB), a chlorotriptyl-O-NH<sub>2</sub> resin (IV) may be reacted with an acid chloride (V) wherein -COOP is a protected carboxylic acid group, to produce a resin-supported protected carboxylic acid (VI).



The protecting group may then be removed from (VI) and the resultant acid coupled with the tricyclic amine (IIA) or (IIB) (analogously to the coupling of (IIA) or (IIB) and (IV) above). Finally the desired hydroxamate compound may be cleaved from the resin with trifluoroacetic acid.


N-hydroxyacylamino compounds of the invention may be prepared by coupling the tricyclic amine (IIA) or (IIB) with the carboxylic acid (VIII) or an activated derivative thereof





in which Z is halogen or other leaving group which is displaced with protected hydroxylamine. The resulting compound is then acylated with either an acid anhydride or acid chloride and the hydroxylamine protecting group removed to give the desired N-hydroxyacylamino compound.

Structures of formula (IIB) may also be prepared by the Pictet-Spengler reaction (1. Pictet, A; Spengler, T. Ber, 1911, 44, 2034; 2. Whaley, W.M.; Govindachari, T.R. Org. React., 1951, 6, 74.) which, in brief involves reaction of tryptamine or tryptophan or derivatives thereof and an aldehyde:



As mentioned above, the compounds with which the invention is concerned are HDAC inhibitors, and may therefore be of use in the treatment of cell proliferative disease, such as cancer, in humans and other mammals.

It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing treatment. Optimum dose levels and frequency of dosing will be determined by clinical trial.

The compounds with which the invention is concerned may be prepared for administration by any route consistent with their pharmacokinetic properties. The orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral



administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

For topical application to the skin, the drug may be made up into a cream, lotion or ointment. Cream or ointment formulations which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceuticals such as the British Pharmacopoeia.

For topical application to the eye, the drug may be made up into a solution or suspension in a suitable sterile aqueous or non aqueous vehicle. Additives, for instance buffers such as sodium metabisulphite or disodium edeate; preservatives including bactericidal and fungicidal agents such as phenyl mercuric acetate or nitrate, benzalkonium chloride or chlorhexidine, and thickening agents such as hypromellose may also be included.

The active ingredient may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can


either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.

The following Example illustrates the preparation of a compound of the invention the HDAC inhibitory properties thereof, are shown in Tables 1 and 2 below. In the Example, the following abbreviations have been used:


DMF:	Dimethylformamide
MeOH:	Methanol
DCM:	Dichloromethane
TBME:	t-Butylmethyl ether
PyBOP	Benzotriazol-1-yloxotripyrrolidinophosphonium hexafluorophosphate
TFA:	Trifluoroacetic acid

### Example 1

Preparation of 8-Oxo-(1, 3, 4, 9-tetrahydro- $\beta$ -carbolin-2-yl)-octanoic acid hydroxyamide




Stage 1 – Immobilisation of linker with chlorotriptyl-O-NH<sub>2</sub> resin




To a round bottomed flask charged with chlorotriyl-O-NH<sub>2</sub> resin (5 g, loading 1.36 mmol/g, 6.8 mmol) and DCM (50 ml) was added diisopropylethylamine (5.27g, 40.8 mmol, 6 eq). Methyl 8-chloro-8-oxooctanoate (4.22 g, 20.4 mmol, 3 eq) was slowly added to the reaction mixture with orbital shaking and the reaction mixture shaken for 48 hours. The resin was filtered and washed, DMF, MeOH, DMF, MeOH, DCM, MeOH, DCM, MeOH x 2, TBME x 2. The resin was dried under vacuum.

### Stage 2 – Saponification



To a round bottomed flask charged with stage 1 resin (5 g, loading 1.36 mmol/g, 6.8 mmol) was added THF (17 ml) and MeOH (17 ml). To the reaction was added a solution of NaOH (1.36 g, 34 mmol, 5 eq) in water (17 ml). The reaction mixture shaken for 48 hours. The resin was filtered and washed with water x 2, MeOH x 2, DMF, MeOH, DMF, MeOH, DCM, MeOH, DCM, MeOH x 2, TBME x 2. The resin was dried under vacuum.

### Stage 3 – Coupling



To a 2 ml 96 well plate charged with stage 2 resin (100 mg per well, loading 1.36 mmol/g, 0.136 mmol) was added a solution of PyBOP (0.21 g, 0.40 mmol, 3 eq) in DCM (0.5 ml) to each well. To one well was added 1,2,3,4-tetrahydro-9H-pyrido[3,4-B]indole (0.14 g, 0.82 mmol, 6 eq) in DCM (0.5 ml) followed by diisopropylethylamine (0.07g, 0.54 mmol, 4 eq). The 96 well plate was sealed and shaken for 16 h. The resin filtered and washed, DMF, MeOH, DMF, MeOH, DCM, MeOH, DCM, MeOH x 2, TBME x 2.

#### Stage 4 – Cleavage

A 2 ml Porvair plate was placed for collection under the 2 ml microlute plate from stage 3. A 2% solution of TFA/DCM (1.5 ml) was dripped through the resin in 0.5 ml aliquots, allowing 5 minutes between each aliquot. The procedure was repeated to give a total of 4 cleavage cycles. The solvent was removed using a Genevac. 8-Oxo-(1, 3, 4, 9-tetrahydro- $\beta$ -carbolin-2-yl)-octanoic acid hydroxyamide (CHR-002504) was obtained as one product from the 96 reactions.  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 10.86 (1H), 10.34 (1H, s), 8.67 (1H, s), 7.36 (1H, m, Ar), 7.27 (1H, m, Ar), 7.01 (1H, m, Ar), 6.95 (1H, m, Ar), 4.64 (2H, s,  $\text{CH}_2\text{N}$ ), 3.75 (2H, m,  $\text{CH}_2$ ), 2.72 and 2.63 (2H, m), 2.41 (2H, m), 2.17 and 1.91 (2H, m), 1.47 (4H, m), 1.26 (4H, m).  $m/z$  [ES] 344 [M+H] $^+$

#### Measurement of biological activities

##### Histone deacetylase activity

The ability of compounds to inhibit histone deacetylase activities was measured using the commercially available HDAC fluorescent activity assay from Biomol. In brief, the *Fluor de Lys<sup>TM</sup>* substrate, a lysine with an epsilon-amino acetylation, is incubated with the source of histone deacetylase activity (HeLa nuclear extract) in the presence or absence of inhibitor. Deacetylation of the substrate sensitises the substrate to *Fluor de Lys<sup>TM</sup>* developer, which generates a fluorophore. Thus, incubation of the substrate with a source of HDAC activity results in an increase in signal that is diminished in the presence of an HDAC inhibitor.

Data are expressed as a percentage of the control, measured in the absence of inhibitor, with background signal being subtracted from all samples, as follows:-

$$\% \text{ activity} = ((S^I - B) / (S^{\circ} - B)) \times 100$$

where  $S^I$  is the signal in the presence of substrate, enzyme and inhibitor,  $S^{\circ}$  is the signal in the presence of substrate, enzyme and the vehicle in which the inhibitor is dissolved, and B is the background signal measured in the absence of enzyme.

IC<sub>50</sub> values were determined by non-linear regression analysis, after fitting the results of eight data points to the equation for sigmoidal dose response with variable slope (% activity against log concentration of compound), using Graphpad Prism software.

Histone deacetylase activity from crude nuclear extract derived from HeLa cells was used for screening. The preparation, purchased from 4C (Seneffe, Belgium), was prepared from HeLa cells harvested whilst in exponential growth phase. The nuclear extract is prepared according to Dignam JD1983 Nucl. Acid. Res. 11, 1475-1489, snap frozen in liquid nitrogen and stored at -80°C. The final buffer composition was 20 mM Hepes, 100 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF and 20 % (v/v) glycerol. IC<sub>50</sub> results were allocated to one of 3 ranges as follows: Range A: IC<sub>50</sub> < 330nM, Range B: IC<sub>50</sub> from 330nM to 1000nM; and Range C: IC<sub>50</sub> > 1000nM.

**Result:** The compound of Example 1 had an IC<sub>50</sub> in Range A in the above assay.

### **HeLa Cell inhibition Assay**

Hela cells growing in log phase were harvested and seeded at 1000 cells/well (200ul final volume) into 96-well tissue culture plates. Following 24h of cell growth cells were treated with compounds (final concentration of 20uM). Plates were then re-incubated for a further 72h before a sulphorhodamine B (SRB) cell viability assay was conducted according to Skehan 1990 J Natl Canc Inst 82, 1107-1112.


Data were expressed as a percentage inhibition of the control, measured in the absence of inhibitor, as follows:-

$$\% \text{ inhibition} = 100 - ((S^i/S^o) \times 100)$$

where  $S^i$  is the signal in the presence of inhibitor and  $S^o$  is the signal in the presence of DMSO.

**Result:** The compound of Example 1 inhibited Hela cell proliferation in the above assay by > 75% at 20 micromolar.

Further compounds of the invention may be prepared by methods analogous to that of Example 1 by using any of the tricyclic amines whose structures are shown in Tables 1A and 1B below and an acid chloride of formula



( $\text{Alk}^1$ ,  $\text{Alk}^2$ , X, n, m and p being as defined in relation to formula (I) above) in place of 1,2,3,4-tetrahydro-9H-pyrido[3,4-B]indole and methyl 8-chloro-8-oxooctanoate of Example 1. For example, the following exemplary compounds of Table 1 were prepared thus, and characterised by mass spectrometry and activity versus HeLa Nuclear Extract HDACs as described above:





Table 1

Example	R	$R_2, R^1_2$	$R_3$	n	$[M+H]^+$	IC50
2	H	$R_2 = \text{H}, R^1_2 = \text{H}$	H	5	330	A
3	$\text{CH}_3\text{O}-$	$R_2 = \text{H}, R^1_2 = \text{H}$	H	6	374	A
4	H	$R_2 = \text{H}, R^1_2 = \text{H}$	$\text{CH}_3\text{OCO}-$	6	402	A
5	H	$R_2 = \text{H}, R^1_2 = \text{H}$	H	7	358	A

6	CH <sub>3</sub> O-	R <sub>2</sub> = H, R <sup>1</sup> <sub>2</sub> = H	H	5	360	A
7	CH <sub>3</sub> O-	R <sub>2</sub> = H, R <sup>1</sup> <sub>2</sub> = H	H	7	388	A
8	H	R <sub>2</sub> = H, R <sup>1</sup> <sub>2</sub> = CF <sub>3</sub> -	H	5	398	B
9	H	R <sub>2</sub> = H, R <sup>1</sup> <sub>2</sub> = CF <sub>3</sub> -	H	6	412	A
10	H	R <sub>2</sub> = H, R <sup>1</sup> <sub>2</sub> = CF <sub>3</sub> -	H	7	426	A
11	H	R <sub>2</sub> = H, R <sup>1</sup> <sub>2</sub> = H	CH <sub>3</sub> OCO-	5	388	B
12	H	R <sub>2</sub> = H, R <sup>1</sup> <sub>2</sub> = H	CH <sub>3</sub> OCO-	7	416	B
13	H	spiro cyclohexyl	H	5	398	B
14	H	spiro cyclohexyl	H	6	412	A
15*	H	R <sub>2</sub> = H, R <sup>1</sup> <sub>2</sub> = H	HOCO-	5	374	B
16*	H	R <sub>2</sub> = H, R <sup>1</sup> <sub>2</sub> = H	HOCO-	6	388	A
17*	H	R <sub>2</sub> = H, R <sup>1</sup> <sub>2</sub> = H	HOCO-	7	402	B

\*Note: the compounds of Examples 15-17 were prepared by saponification of the corresponding methyl esters of Examples 11, 4 and 7, as follows:



To a glass vial charged with resin (100 mg, loading 0.94 mmol/g, 0.094 mmol) was added a solution of NaOH (19 mg, 0.47 mmol, 5eq) in H<sub>2</sub>O (0.35 ml), THF (0.35 ml) and methanol (0.35 ml). The vial was capped and the reaction shaken for 48 h. The resin was filtered and washed with DMF, DCM, DMF, DCM, MeOH, DCM, MeOH x 2, TBME x 2. The resin was dried under vacuum.

Table 1A















Table 1B




Table 1B (cont)


















Table 1B (cont)




Table 1B (cont)




Table 1B (cont)











Table 1B<sub>o</sub> (cont)

## Claims:

1. A compound of formula (IA) or (IB), or a salt, hydrate or solvate thereof.



wherein

fused rings A<sup>1</sup> and A<sup>2</sup> are optionally substituted;

R<sub>1</sub> represents a radical of formula  $-(\text{Alk}^1)_n-(\text{X})_m-(\text{Alk}^2)_p-\text{Z}$  wherein

Z represents a radical of formula  $-\text{C}(=\text{O})\text{NH}(\text{OH})$ , or  $-\text{N}(\text{OH})\text{C}(=\text{O})\text{Y}$  wherein Y represents hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, a phenyl or cycloalkyl ring, or a monocyclic heterocyclic radical having 5 or 6 ring atoms;

Alk<sup>1</sup> represents an optionally substituted, straight or branched, C<sub>1</sub>-C<sub>6</sub> alkylene radical,

Alk<sup>2</sup> represents an optionally substituted, straight or branched, C<sub>1</sub>-C<sub>6</sub> alkylene, C<sub>2</sub>-C<sub>6</sub> alkenylene or C<sub>2</sub>-C<sub>6</sub> alkynylene radical which may optionally contain an ether ( $-\text{O}-$ ), thioether ( $-\text{S}-$ ) or amino ( $-\text{NR}^{\text{A}}$ ) link wherein R<sup>A</sup> is hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl;

X represents an optionally substituted phenyl or 5- or 6-membered heteroaryl ring; and

n, m and p are independently 0 or 1, provided that at least one of n, m and p is 1 and the length of radical  $-(\text{Alk}^1)_n-(\text{X})_m-(\text{Alk}^2)_p-$  is equivalent to that of a hydrocarbon chain of from 2-10 carbon atoms;

R<sub>12</sub> is hydrogen and R<sub>2</sub> is (a) an optional substituent or (b) a radical of formula

$-(\text{Alk}^3)_r\text{-Q}$  wherein  $r$  is 0 or 1,  $\text{Alk}^3$  represents an optionally substituted, straight or branched,  $\text{C}_1\text{-C}_6$  alkylene,  $\text{C}_2\text{-C}_6$  alkenylene or  $\text{C}_2\text{-C}_6$  alkynylene radical and  $\text{Q}$  is hydrogen or an optionally substituted carbocyclic or heterocyclic group; or  $\text{R}_1^2$  and  $\text{R}_2$  taken together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring;

$\text{R}_1^3$  is hydrogen and  $\text{R}_3$  is (i) an optional substituent or (ii) a radical of formula  $-(\text{Alk}^3)_r\text{-Q}$  wherein  $r$  is 0 or 1,  $\text{Alk}^3$  represents an optionally substituted, straight or branched,  $\text{C}_1\text{-C}_6$  alkylene,  $\text{C}_2\text{-C}_6$  alkenylene or  $\text{C}_2\text{-C}_6$  alkynylene radical and  $\text{Q}$  is hydrogen or an optionally substituted carbocyclic or heterocyclic group; or  $\text{R}_1^3$  and  $\text{R}_3$  taken together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring; and

$\text{R}_4$  is hydrogen or  $\text{C}_1\text{-C}_6$  alkyl.

2. A compound as claimed in claim 1 wherein the group  $\text{Z}$  in  $\text{R}_1$  is a hydroxamate group  $\text{-C(=O)NHOH}$  or N-hydroxyformylamino group  $\text{-N(OH)C(=O)H}$ .
3. A compound as claimed in claim 1 or claim 2 wherein the length of the radical  $-(\text{Alk}^1)_n\text{-(X)}_m\text{-(Alk}^2)_p\text{-}$  in  $\text{R}_1$  is equivalent to a chain of from 2 to 10 carbons, or 4 to 9 carbons, or 5 to 8 carbons.
4. A compound as claimed in claim 1 or claim 2 wherein the length of the radical  $-(\text{Alk}^1)_n\text{-(X)}_m\text{-(Alk}^2)_p\text{-}$  in  $\text{R}_1$  is equivalent to a chain of 6 carbons.
5. A compound as claimed in any of the preceding claims wherein in the radical  $-(\text{Alk}^1)_n\text{-(X)}_m\text{-(Alk}^2)_p\text{-}$ ,  $\text{Alk}^1$  and  $\text{Alk}^2$  when present independently represent an unsubstituted, unbranched,  $\text{C}_1\text{-C}_6$  alkylene,  $\text{C}_2\text{-C}_6$  alkenylene or  $\text{C}_2\text{-C}_6$  alkynylene radical.




6. A compound as claimed in any of the preceding claims wherein in the radical  $-(\text{Alk}^1)_n-(\text{X})_m-(\text{Alk}^2)_p-$ ,  $\text{Alk}^1$  and  $\text{Alk}^2$  when present independently represent  $-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}=\text{CH}-$ ,  $-\text{CH}=\text{CHCH}_2-$ ,  $-\text{CH}_2\text{CH}=\text{CH}-$ ,  $\text{CH}_2\text{CH}=\text{CHCH}_2-\text{C}\equiv\text{C}-$ ,  $-\text{C}\equiv\text{CCH}_2-$ ,  $-\text{CH}_2\text{C}\equiv\text{C}-$  or  $-\text{CH}_2\text{C}\equiv\text{CCH}_2-$ .
7. A compound as claimed in any of the preceding claims wherein the radical  $-(\text{Alk}^1)_n-(\text{X})_m-(\text{Alk}^2)_p-$ , X when present represents an unsubstituted phenyl ring.
8. A compound as claimed in any of the preceding claims wherein the linker radical  $-(\text{Alk}^1)_n-(\text{X})_m-(\text{Alk}^2)_p-$ , m is 0 and n and/or p is/are 1.
9. A compound as claimed in any of claims 1 to 4 wherein the linker radical  $-(\text{Alk}^1)_n-(\text{X})_m-(\text{Alk}^2)_p-$  is an unsubstituted, unbranched, saturated hydrocarbon chain of 4 to 9 carbons, or 5 to 8 carbons, or 6 carbons..
10. A compound as claimed in any of the preceding claims wherein  $\text{R}^1_2$  is hydrogen and  $\text{R}_2$  is trifluoromethyl, methyl, ethyl n- and iso-propyl, methoxy, ethoxy, methylenedioxy, ethylenedioxy, amino, mono- and di-methylamino, mono- and di-ethylamino, nitro, cyano, fluoro, chloro, bromo, or methylsulfonylamino.
11. A compound as claimed in any of the preceding claims wherein  $\text{R}^1_2$  is hydrogen and  $\text{R}_2$  is a radical of formula  $-(\text{Alk}^3)_r-\text{Q}$  wherein r is 0 or 1;  $\text{Alk}^3$  is  $-\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$ ,  $-\text{CH}=\text{CH}-$ ,  $-\text{CH}=\text{CHCH}_2-$ ,  $-\text{CH}_2\text{CH}=\text{CH}-$ ,  $\text{CH}_2\text{CH}=\text{CHCH}_2-\text{C}\equiv\text{C}-$ ,  $-\text{C}\equiv\text{CCH}_2-$ ,  $-\text{CH}_2\text{C}\equiv\text{C}-$ ,  $-\text{CH}_2\text{C}\equiv\text{CCH}_2-$  or  $-\text{CH}_2\text{W}-$ ,  $-\text{CH}_2\text{CH}_2\text{W}-$ ,  $-\text{CH}_2\text{CH}_2\text{WCH}_2-$ ,  $-\text{CH}_2\text{WCH}_2\text{CH}_2-$ ,  $-\text{CH}_2\text{WCH}_2\text{CH}_2\text{WCH}_2-$ , or  $-\text{WCH}_2\text{CH}_2-$  where W is  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{NH}-$  or  $-\text{N}(\text{CH}_3)-$ ; and Q is hydrogen or an optionally substituted phenyl, pyridyl, pyrimidinyl, thienyl, furanyl, cyclopropyl, cyclopentyl, cyclohexyl, piperidinyl, or morpholinyl.

12. A compound as claimed in claim 11 wherein Q is phenyl, 4-pyridyl, or pyrimidin-2-yl.
13. A compound as claimed in any of claims 1 to 9 wherein  $R^1_2$  and  $R_2$  taken together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring.
14. A compound as claimed in any of the preceding claims wherein  $R^1_3$  is hydrogen and  $R_3$  is trifluoromethyl, methyl, ethyl n- and iso-propyl, methoxy, ethoxy, methylenedioxy, ethylenedioxy, amino, mono- and di-methylamino, mono- and di-ethylamino, nitro, cyano, fluoro, chloro, bromo, or methylsulfonylamino.
15. A compound as claimed in any of the preceding claims wherein  $R^1_3$  is hydrogen and  $R_3$  is a radical of formula  $-(Alk^3)_r-Q$  wherein r is 0 or 1;  $Alk^3$  is  $-CH_2-$ ,  $-CH_2CH_2-$ ,  $-CH_2CH_2CH_2-$ ,  $-CH_2CH_2CH_2CH_2-$ ,  $-CH=CH-$ ,  $-CH=CHCH_2-$ ,  $-CH_2CH=CH-$ ,  $CH_2CH=CHCH_2-C\equiv C-$ ,  $-C\equiv CCH_2-$ ,  $-CH_2C\equiv C-$ ,  $-CH_2C\equiv CCH_2-$  or  $-CH_2W-$ ,  $-CH_2CH_2W-$ ,  $-CH_2CH_2WCH_2-$ ,  $-CH_2WCH_2CH_2-$ ,  $-CH_2WCH_2CH_2WCH_2-$ , or  $-WCH_2CH_2-$  where W is  $-O-$ ,  $-S-$ ,  $-NH-$  or  $-N(CH_3)-$ ; and Q is hydrogen or an optionally substituted phenyl, pyridyl, pyrimidinyl, thienyl, furanyl, cyclopropyl, cyclopentyl, cyclohexyl, piperidinyl, or morpholinyl.
16. A compound as claimed in claim 15 wherein Q is phenyl, 4-pyridyl, or pyrimidin-2-yl.
17. A compound as claimed in any of claims 1 to 13 wherein  $R^1_3$  and  $R_3$  taken together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring.
18. A compound as claimed in any of the preceding claims wherein  $R_4$  is hydrogen, methyl, ethyl or n- or iso-propyl.

19. A compound as claimed in any of the preceding claims wherein optional substituents in the fused rings A<sup>1</sup> and A<sup>2</sup> are selected from trifluoromethyl, methyl, ethyl n- and iso-propyl, methoxy, ethoxy, methylenedioxy, ethylenedioxy, amino, mono- and di-methylamino, mono- and di-ethylamino, nitro, cyano, fluoro, chloro, bromo, and methylsulfonylamino.
20. A pharmaceutical composition comprising a compound as claimed in any of the preceding claims, together with a pharmaceutically acceptable carrier.
21. The use of a compound as claimed in any of claims 1 to 19 in the preparation of a composition for inhibiting the activity of an HDAC enzyme
22. The use as claimed in claim 22 for the inhibition of HDAC1 activity.
23. The use as claimed in claim 21 or claim 22 for the inhibition of HDAC activity, *ex vivo* or *in vivo*.
24. The use of a compound as claimed in any of claims 1 to 19 in the preparation of a composition for the treatment of cell-proliferation disease, polyglutamine disease, neurogenerative disease, autoimmune disease, organ transplant rejection, diabetes, haematological disorders or infection.
25. The use as claimed in claim 24 wherein the disease is cancer, Huntingdon disease, or Alzheimer disease.
26. A method for the treatment of a condition selected from the group consisting of cell-proliferation disease, polyglutamine disease, neurogenerative disease, autoimmune disease, organ transplant rejection, diabetes, haematological disorders and infection, which method comprises administering to a subject suffering such disease an effective amount of a compound as claimed in any of claims 1 to 19.

27. A method as claimed in claim 24 wherein the disease is cancer, Huntingdon disease, or Alzheimer disease.



BEST AVAILABLE COPY

PCT/GB2004/002504

